NCT05282004 - Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 16, 2022

Primary Completion Date

September 7, 2022

Study Completion Date

September 7, 2022

Conditions

Neovascular Age-related Macular Degeneration (nAMD)

Interventions

DRUG

SOK583A1

SOK583A1 will be provided in a vial kit, with 40 mg/mL of aflibercept solution for IVT injection (2 mg/0.05 mL)

Trial Locations (5)

Sandoz Investigational Site, Liverpool

Sandoz Investigational Site, Lynchburg

Sandoz Investigational Site, Marietta

Sandoz Investigational Site, Oak Forest

Sandoz Investigational Site, Poway